Baxter invests $650 million annually in R&D and home dialysis is one of our largest product segments. Dialysis works by filtering a water-based solution called dialysate through a patient’s bloodstream to remove excess waste, a process that simulates the functioning of a healthy kidney.
Today, rather than travel to dialysis centers, many patients with chronic kidney disease (CKD) receive their treatment on home dialysis machines. For home dialysis machines to work properly, the water needs to be free of “hardness” or mineral content; otherwise, precipitates will form and degrade the machine’s performance.
Hardness in water is not a problem unique to dialysis and is typically removed using “water softeners” that filter out minerals through a process known as “ion exchange.” However, water softeners and similar technologies don’t work well for home dialysis machines because they:
Take up a significant amount of space inside the machine
Require frequent maintenance (e.g. replenishment of salt reservoir, replacement of resin cartridges)
Use separation processes (e.g., membrane filtration) that produce wastewater
We’re looking to collaborate with researchers to develop efficient, low-maintenance technologies that can reduce water hardness from an upper limit of 450mg/L.
You can assume the feed water is sourced from either municipal water supplies or private well water and is compliant with the drinking-water quality guidelines of the World Health Organization.
The operating conditions of the dialysis machine are:
Baxter is a global Fortune 500 healthcare and medical device company based in Deerfield, Illinois that develops products to treat kidney disease, hemophilia, immune disorders and other chronic and acute medical conditions.
Learn more